Refreshing results…
RHOA L57V drives the development of diffuse gastric cancer through IGF1R-PAK1-YAP1 signaling
UploadConvergence of Targeted and Immune Therapies for the Treatment of Oncogene-Driven Cancers
Download from aacrjournals.orgCombination Therapies with CDK4/6 Inhibitors to Treat KRAS-Mutant Pancreatic Cancer
Download from aacrjournals.orgFunctional and biological heterogeneity of KRAS Q61 mutations
UploadAtypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer
Download from aacrjournals.orgCombination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer
Download from www.nature.comKRAS Suppression-Induced Degradation of MYC is Antagonized by a MEK5-ERK5 Compensatory Mechanism
UploadEvaluation of the selectivity and sensitivity of isoform- and mutation-specific RAS antibodies
Download from europepmc.orgEct2-Dependent rRNA Synthesis Is Required for KRAS-TRP53 -Driven Lung Adenocarcinoma
Download from europepmc.orgThe role of wild type RAS isoforms in cancer
Download from www.ncbi.nlm.nih.govINO80 is required for oncogenic transcription and tumor growth in non-small cell lung cancer
Download from www.nature.comERK/MAPK Signaling Drives Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma
Download from aacrjournals.orgRPL23 Links Oncogenic RAS Signaling to p53-Mediated Tumor Suppression
Download from aacrjournals.orgMissing publications? Search for publications with a matching author name.